Connect with us

Health

Lange warns ‘Section 301’ investigation threatens Turnberry trade deal

SHARE:

Published

50 minutes ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Trump administration's decision to launch a Section 301 investigation into Germany's pharmaceutical pricing system has triggered a sharp rebuke from the European Parliament’s Trade Committee Chair Bernd Lange (S&D, Germany).

“Unfortunately, this is no bad joke: the US is launching a 301 tariff investigation over a German draft law on medicine prices. That is interference in national sovereignty. Absolute no-go! Good that the EP secured a safety net against Turnberry violations,” said the MEP.

The investigation could result in the imposition of retaliatory tariffs or other trade measures if it concludes that Germany's policies harm America's economic interests.

The move came just days after the European Parliament gave conditional approval to legislation implementing the Turnberry Agreement, which caps most US tariffs on EU goods at 15%, including branded pharmaceuticals. Parliament insisted on the inclusion of safeguards allowing the EU to suspend elements of the agreement should Washington breach its commitments.

The investigation also drew a firm response from German Chancellor Friedrich Merz, who rejected the notion that Washington should influence domestic healthcare policy.

"As far as the reimbursement of modern, innovative medicines by our health insurance funds is concerned, that is a decision that falls within our national remit," he said. "This is a matter 

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending